The present invention relates to a pharmaceutical composition for oral administration comprising a non-bile farnesoid X receptor (FXR) agonist 2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2- (trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3- benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one lipid excipient； to a capsule for oral administration comprising said pharmaceutical composition； to the use of said pharmaceutical composition for the treatment of a FXR mediated disorder or condition； and to a process for preparing said pharmaceutical composition.
